Visceral Adipose Tissue (VAT): What It Is, Why It's the Most Dangerous Fat in Your Body, and How a DEXA Scan Measures It

Visceral Adipose Tissue (VAT) is the deep abdominal fat that surrounds your liver, pancreas, and intestines. It is metabolically active, drives inflammation, insulin resistance, and cardiovascular disease, and it is the single most dangerous fat depot in the human body. You cannot see it in the mirror. You cannot measure it with a tape measure. A whole-body DEXA scan can measure it in 10 minutes.

Find a DEXASCAN.com clinic near you →

What Is Visceral Adipose Tissue?

Your body stores fat in two structurally distinct compartments:

  • Subcutaneous adipose tissue — the soft fat layer directly under your skin. You can pinch it. It is the fat most people associate with "being overweight."
  • Visceral adipose tissue (VAT) — the fat packed deep inside your abdominal cavity, wrapped around and between your internal organs: liver, pancreas, intestines, and kidneys.

These two fat depots look similar but behave nothing alike. Subcutaneous fat is largely a passive storage tissue. Visceral fat is a metabolically and hormonally active endocrine organ. It secretes pro-inflammatory cytokines (TNF-α, IL-6), free fatty acids, and adipokines that drain directly into the portal vein and reach the liver first — driving insulin resistance, dyslipidemia, hepatic steatosis, and systemic inflammation in ways subcutaneous fat simply does not.1

This is why two people with identical body weight, identical BMI, and identical total body fat can have completely different metabolic health profiles. The one with high VAT is at substantially elevated risk. The one with low VAT, even if heavier overall, may be metabolically healthy.

VAT is the reason BMI fails as a health metric. It is also the reason a whole-body DEXA scan at a DEXASCAN.com clinic is the single most informative test you can take for cardiometabolic risk stratification.

Why VAT Is the Most Dangerous Fat in Your Body

The mechanisms by which visceral fat causes disease are now well-established:

1. Insulin resistance and type 2 diabetes

VAT releases free fatty acids directly into the portal vein, where they impair hepatic insulin signaling and drive insulin resistance — the precursor to type 2 diabetes.1 Research on DEXA-measured VAT in young, otherwise healthy adults has shown that VAT correlates with cardiometabolic risk markers (blood pressure, triglycerides, HDL cholesterol, insulin, HOMA-IR) even before traditional risk factors become abnormal.2

2. Cardiovascular disease and atherosclerosis

Visceral fat is the strongest adipose-tissue predictor of cardiovascular disease. The Framingham Heart Study established the link between abdominal adiposity and CVD risk decades ago, and modern imaging confirms VAT's role in promoting systemic inflammation, endothelial dysfunction, and atherosclerotic plaque development.3

A 2025 NHANES-based study established sex-specific VAT thresholds for cardiovascular disease risk stratification:

  • Men: VAT volume ≥ 387.5 cm³ associated with elevated CVD risk
  • Women: VAT volume ≥ 312.0 cm³ associated with elevated CVD risk

The authors of that study explicitly noted that BMI "fails to capture critical pathophysiological distinctions in regional adiposity deposition, conflating lean mass with fat mass and disregarding visceral adipose tissue distribution patterns." Their conclusion: BMI may misclassify cardiometabolic risk, either underestimating VAT-driven pathology in normal-weight individuals or overestimating it in muscular phenotypes.4

3. Dyslipidemia and metabolic syndrome

A landmark study published in Diabetes Care identified critical VAT thresholds in postmenopausal women: those with VAT ≥ 106 cm² were 2.5 times more likely to have low HDL cholesterol, and those with VAT ≥ 163 cm² were 5.5 times more likely to have low HDL and approximately 4 times more likely to have a high LDL/HDL ratio.5

4. Inflammation and accelerated aging

VAT secretes inflammatory mediators that contribute to chronic low-grade systemic inflammation — a state strongly associated with accelerated biological aging, neurodegeneration, and cancer risk.16

5. Cancer risk

The relationship between visceral adiposity and cancer is increasingly clear. Multiple cohort studies link VAT to elevated risk of colorectal, postmenopausal breast, pancreatic, endometrial, and liver cancers — risks that are not fully captured by BMI alone.1

The bottom line: VAT is the most clinically dangerous fat depot in the body, and it is invisible to every screening tool except direct imaging.

Why You Cannot Measure VAT With a Tape Measure or a Scale

Several methods try to estimate visceral fat. Most of them are wrong by a wide margin:

Method Direct measurement of VAT? Accuracy
BMI No Cannot distinguish fat from muscle, cannot localize fat
Waist circumference No — proxy only Better than BMI, but cannot distinguish VAT from subcutaneous fat
Waist-to-hip ratio No — proxy only Modest improvement over WC alone
Smart scale / BIA No — estimate only Poor accuracy, highly variable
DEXA scan Yes — direct measurement Excellent agreement with CT, far lower radiation and cost
CT scan Yes — gold standard High radiation, high cost, not practical for screening
MRI Yes — gold standard Very expensive, limited access, slow

A pivotal Indian DEXA study comparing DEXA-measured VAT against waist circumference, BMI, and total fat percent in 300 women found that DEXA-VAT was a better predictor of cardiometabolic risk than waist circumference, BMI, or total body fat percentage in postmenopausal women (AUC 0.68 vs 0.62, 0.60, and 0.5, respectively).7

The implication is straightforward: if you have been relying on a waist measurement or a BMI to gauge your visceral fat risk, you have been working with a proxy of a proxy. A DEXA scan gives you the actual number.

How DEXA Measures Visceral Fat

A whole-body DEXA scan uses two low-dose X-ray energies that attenuate differently through bone, lean soft tissue, and fat. Modern DEXA software then applies validated algorithms to isolate visceral adipose tissue within the android region (the abdominal section between the ribcage and pelvis), separating it from the subcutaneous fat layer in the same region.

Specifically, the scanner reports VAT as:

  • VAT mass (grams)
  • VAT volume (cm³)
  • VAT area (cm²) at the L4-L5 level (the same anatomical reference used by CT-based VAT measurement)

DEXA-derived VAT shows excellent agreement with CT and MRI — the gold standards — at a fraction of the cost, time, and radiation exposure. A whole-body DEXA scan delivers approximately 4–5 µSv of radiation, about half a day of natural background radiation, compared to ~50–100 µSv for quantitative CT.89

In other words: you get clinical-grade visceral fat measurement in about 10 minutes, for less radiation than a transcontinental flight, and for a small fraction of the cost of an MRI.

VAT Thresholds: What Numbers Should You Be Targeting?

The clinical literature has converged on several useful reference points. Note that VAT can be reported in mass (grams), volume (cm³), or area (cm²) depending on your scanner and software — your DEXA report will clarify which.

General VAT thresholds (cross-referenced from major studies)

Risk category Approximate VAT mass Notes
Low / optimal < 500 g Below most cardiometabolic risk thresholds
Moderate 500 – 1,000 g Increasing CVD and insulin resistance risk
High 1,000 – 1,500 g Substantially elevated cardiometabolic risk
Very high > 1,500 g High risk of metabolic syndrome, T2D, CVD

Volume-based thresholds (2025 NHANES analysis)

  • Men: ≥ 387.5 cm³ associated with elevated CVD risk
  • Women: ≥ 312.0 cm³ associated with elevated CVD risk4

Area-based thresholds (postmenopausal women, Diabetes Care)

  • VAT ≥ 106 cm²: elevated CHD risk factors
  • VAT ≥ 163 cm²: substantially elevated risk5

The most important point is not the specific number — it is the trend. Trending VAT downward over 6–12 months on the same scanner is one of the most powerful health signals you can generate.

Track your VAT trend with a DEXASCAN.com follow-up scan →

How to Reduce Visceral Fat: What the Evidence Actually Supports

Unlike subcutaneous fat, which responds primarily to caloric balance, visceral fat is exquisitely responsive to exercise — particularly aerobic exercise and high-intensity interval training (HIIT). The evidence base is strong and consistent.

1. Exercise — the highest-leverage intervention for VAT specifically

A 2023 systematic review and meta-analysis of randomized controlled trials examining dose-response effects of exercise versus caloric restriction on visceral adiposity in overweight and obese adults concluded:

"Both interventions can effectively reduce visceral fat... However, only exercise showed a dose-dependent relationship between energy expenditure and visceral fat."10

Translation: every additional unit of exercise produces additional visceral fat reduction, in a way that caloric restriction alone does not.

A 2022 meta-analysis specifically comparing exercise modalities for visceral fat reduction in young adults found that aerobic exercise and HIIT were the most effective, with HIIT producing the largest reductions in many studies.11 A 12-week randomized trial in obese young women comparing HIIT to moderate-intensity continuous training found comparable reductions in abdominal visceral fat area between the two modalities — both significantly outperforming controls.12

2. Diet — particularly reductions in refined carbohydrates and added sugar

A 2025 dietary intervention study published in Frontiers in Endocrinology confirmed that visceral adiposity loss is directly associated with improvement in cardiometabolic markers, including reductions in inflammation, triglycerides, and insulin resistance.13 A 2025 Medical News Today-covered review concluded that the combination of diet and exercise produced greater visceral fat reduction than either alone.14

3. Combined exercise plus dietary intervention

A 2025 systematic review and meta-regression of randomized clinical trials evaluated the effect of combined exercise plus dietary intervention versus diet alone on ectopic fat depots — including VAT, liver fat, pancreatic fat, and pericardial fat — and found combined interventions consistently outperformed diet alone for visceral fat reduction.15

4. Sleep, stress, and cortisol management

Chronic short sleep (<7 hours) and chronic stress are independently associated with elevated cortisol and preferential visceral fat accumulation — independent of caloric intake. The visceral fat depot is more responsive to cortisol than the subcutaneous depot.

5. GLP-1 receptor agonists — but with a measurement-required caveat

GLP-1 medications produce preferential reductions in visceral fat over subcutaneous fat during weight loss, which is an excellent outcome. However, the magnitude of this preferential VAT loss varies considerably between patients and can only be confirmed by direct measurement.16 A pre-GLP-1 and 3-month-follow-up DEXA scan is the only way to verify that your medication is actually doing what you hope it is doing.

Why a DEXA Scan Is the Right Place to Measure VAT

A whole-body DEXA scan at a DEXASCAN.com network clinic delivers a complete cardiometabolic risk picture in a single 7–10 minute appointment:

  • Visceral adipose tissue (VAT) — the dangerous deep abdominal fat
  • Subcutaneous fat — measured separately, region by region
  • Fat Mass Index (FMI) — your total body fat scaled to height
  • Appendicular Lean Mass Index (ALMI) — your functional muscle reserve
  • Bone mineral density — your osteoporosis baseline
  • Android/gynoid ratio — the apple-vs-pear pattern that further refines risk

No other single test produces all six measurements together. 

For the muscle side of the equation, see our deep-dive: Appendicular Lean Mass Index (ALMI): The DEXA Scan Number That Predicts How Well You'll Age.

For the total fat side of the equation, see: Fat Mass Index (FMI) vs BMI: Why the Number Your Doctor Uses Is Hiding Your Real Health Risk.

Track Your VAT in the DEXA Scan App

VAT moves slowly. A single number is useful; a long-term VAT trend is what changes outcomes. The DEXA Scan app, available on iOS and Android, lets you:

  • Store every DEXA scan in one place
  • Visualize your VAT, FMI, ALMI, and bone density trends over time
  • Compare your numbers to age- and sex-matched reference ranges
  • Receive evidence-based guidance based on your specific results
  • Book your next scan at any DEXASCAN.com network clinic

Download the DEXA Scan app →

Frequently Asked Questions About Visceral Fat

What is the difference between visceral fat and belly fat?

"Belly fat" colloquially refers to any abdominal fat, but it includes both subcutaneous fat (just under the skin) and visceral fat (deep around the organs). They look similar from the outside but behave very differently metabolically. Visceral fat is the dangerous component. You can have a relatively flat stomach and still have significant visceral fat — this is one reason direct measurement matters.

Can you have high visceral fat at a normal BMI?

Yes, and this is common. The condition is sometimes called "TOFI" — thin outside, fat inside. People with normal BMI but high visceral fat have cardiometabolic risk profiles that look more like the obese category and are routinely missed by BMI-based screening.4

How accurate is DEXA for measuring visceral fat?

DEXA-measured VAT shows excellent agreement with CT-measured VAT, the historical gold standard. Multiple validation studies confirm DEXA as a reliable, low-radiation, low-cost alternative for routine VAT measurement.79

How often should I measure my VAT?

For most adults, every 3-6 months is appropriate. For people undergoing active interventions — starting GLP-1 medications, beginning a structured exercise program, modifying diet significantly — every 3–4 months is reasonable to detect trends.

What is the fastest way to reduce visceral fat?

Aerobic exercise and HIIT produce the largest, fastest reductions in visceral fat, particularly when combined with dietary changes that reduce refined carbohydrates and added sugar. Visceral fat tends to mobilize before subcutaneous fat during exercise interventions — meaning you may see metabolic improvements before you see scale changes.1011

Does spot reduction work for visceral fat?

You cannot "target" visceral fat with abdominal exercises (crunches, sit-ups). Visceral fat responds to systemic interventions — aerobic exercise, HIIT, dietary change, sleep, and stress management — not to localized resistance work in the abdomen.

The Bottom Line

Visceral fat is the most clinically dangerous fat depot in your body. It is invisible to BMI, invisible to your scale, and only loosely captured by a tape measure. The only way to know your real number is to measure it directly.

A whole-body DEXA scan at a DEXASCAN.com clinic gives you that number in about 10 minutes.

Find a DEXASCAN.com clinic near you and book your whole-body scan →

Download the DEXA Scan app to track your VAT trend →

Read next:

References

Medical disclaimer: This article is for educational purposes and does not constitute medical advice. Clinical interpretation of body composition data should be conducted in partnership with a qualified healthcare provider.

©All rights reserved. DEXASCAN.com — the national network for whole-body DEXA scanning.

Footnotes

1. Visceral Adiposity and Cardiometabolic Risk: Clinical Implications. Cardiology in Review. 2024. Available at: https://journals.lww.com/cardiologyinreview/fulltext/9900/visceral_adiposity_and_cardiometabolic_risk_.545.aspx ↩ ↩2 ↩3 ↩4

2. DXA-Determined Visceral Adipose Tissue Is Associated with Cardiometabolic Risk Factors Even in Healthy Young Adults from the Nutritionists' Health Study — NutriHS. Diabetes. 2018. Available at: https://diabetes.diabetesjournals.org/content/67/Supplement_1/2360-PUB ↩

3. Framingham Heart Study and abdominal adiposity — cardiovascular risk evidence base, summarized in: Visceral adiposity loss is associated with improvement in cardiometabolic markers: findings from a dietary intervention study. Frontiers in Endocrinology. 2025. Available at: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1576599/full ↩

4. Visceral Adiposity Thresholds for Cardiovascular Risk Stratification: A Simplified Biomarker-Driven Model. Obesity. 2025. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477109/ ↩ ↩2 ↩3

5. Nicklas BJ, Penninx BWJH, Ryan AS, et al. Visceral Adipose Tissue Cutoffs Associated With Metabolic Risk Factors for Coronary Heart Disease in Women. Diabetes Care. 2003;26(5):1413–1420. Available at: https://diabetesjournals.org/care/article/26/5/1413/24457/ ↩ ↩2

6. Dietary Intervention, When Not Associated With Exercise, Upregulates Irisin/FNDC5 While Reducing Visceral Adiposity Markers in Obese Rats. PMC. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414258/ ↩

7. DXA Measured Visceral Adipose Tissue, Total Fat, Anthropometric Indices and Its Association With Cardiometabolic Risk Factors in Mother-Daughter Pairs From India. Endocrine Practice. 2020. Available at: https://pubmed.ncbi.nlm.nih.gov/32651111/ ↩ ↩2

8. Radiation protection of patients during DXA. International Atomic Energy Agency. Available at: https://www.iaea.org/resources/rpop/health-professionals/other-specialities-and-imaging-modalities/dxa-bone-mineral-densitometry/patients ↩

9. Dose-response effects of exercise and caloric restriction on visceral adiposity in overweight and obese adults: a systematic review and meta-analysis of randomised controlled trials. British Journal of Sports Medicine. 2023. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423480/ ↩ ↩2

10. Effects of different exercise types on visceral fat in young individuals with obesity aged 6–24 years old: A systematic review and meta-analysis. Frontiers in Physiology. 2022. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562999/ ↩ ↩2

11. Comparable Effects of High-Intensity Interval Training and Prolonged Continuous Exercise Training on Abdominal Visceral Fat Reduction in Obese Young Women. Journal of Diabetes Research. 2017. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5237463/ ↩

12. Visceral adiposity loss is associated with improvement in cardiometabolic markers: findings from a dietary intervention study. Frontiers in Endocrinology. 2025. Available at: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1576599/full ↩

13. Fat loss: Study finds diet, exercise combination may be most effective. Medical News Today. 2025. Available at: https://www.medicalnewstoday.com/articles/diet-exercise-study-best-strategy-reducing-belly-fat-weight-loss ↩

14. The Impact of Exercise Training Plus Dietary Interventions on Ectopic Fat in Population with Overweight/Obesity. Advances in Nutrition. 2025. Available at: https://www.sciencedirect.com/science/article/pii/S2475299125000332 ↩

15. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. Cell Reports Medicine. 2026. Available at: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00082-0 ↩

Back to blog